LOGIN  |  REGISTER
Astria Therapeutics
Viking Therapeutics

Therma Bright Announces Change of Auditor

September 29, 2023 | Last Trade: C$0.03 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it has changed its auditors from HS & Partners LLP ("Former Auditor") to Zeifmans LLP ("Successor Auditor"). At the request of the Company, the Former Auditor was terminated as the auditor of the Company effective February 22, 2023, and the board of directors of the Company appointed the Successor Auditor as the Company's auditor effective February 22, 2023. The change of auditor has been approved by the Company's board of directors and its audit committee.

There were no reservations in the Former Auditor's reports in connection with the auditors of the Company's two most recently completed fiscal years. There are no reportable events including disagreements, consultations, or unresolved issues as defined ‎in National Instrument 51-102 - Continuous Disclosure Obligations ("NI 51-102") (Part 4.11) between the Company and the Former Auditor.‎

In accordance with NI 51-102, the notice of change of auditor, together with the required letters from the Former Auditor and the Successor Auditor, both of which are dated September 7, 2023, have been reviewed by the board of directors of the Company and filed on SEDAR+.

In compliance with applicable regulatory requirements, the appointment of the Successor Auditor will be brought before the next shareholders' meeting.

About Therma Bright Inc.

Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

Therma Bright Inc.
Rob Fia, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as the appointment of a Successor Auditor as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB